{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:56:07Z","timestamp":1790787367201,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:00:00Z","timestamp":1761091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Autoimmune rheumatic diseases (ARDs) are chronic inflammatory disorders where B cells play a key role. Traditional B-cell-targeted therapies have limitations, whereas CAR-T-cell therapy, which aims for a broader reset of the B-cell compartment by targeting B-cell surface markers such as CD19 or B-cell maturation antigen (BCMA), has unique advantages. Currently, most CAR-T cell trials for ARDs are in the early stages, with 64.29% (36\/56 trials) of studies being phase I trials and only 7.14% (4\/56 trials) progressing to phase II trials, primarily focusing on conditions, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN). Geographically, clinical research is predominantly led by China (48% of trials [27\/56 trials]) and the United States (34% of trials [19\/56 trials]), although large-scale global collaborations remain limited, with only 3.6% (2\/56 trials) of projects involving both U.S. and Chinese teams. Funding for these studies is driven primarily by non-leading pharmaceutical firms (75% [42\/56 trials] of sponsors). Despite promising efficacy, e.g., CD19-targeted CAR-T cell therapy has induced significant clinical remission in refractory SLE patients, challenges remain, including high costs, complex production, and safety risks. Future progress requires expanding trials, optimizing CAR constructs, enhancing collaboration, and establishing safety monitoring networks, to promote the application of CAR-T cell therapy in ARDs and advance precision medicine.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1630569","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:24Z","timestamp":1761111144000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["CAR-T cell therapies in autoimmune rheumatic diseases: a brief report on the clinical trial landscape, current status, and future perspectives"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su-Hua","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100129","article-title":"Autoimmune rheumatic diseases: One or many diseases","volume":"4","author":"Moutsopoulos","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-41021-00652-41589","article-title":"Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases","volume":"17","author":"Szekanecz","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.142109","article-title":"Prevention of autoimmune rheumatic disease: state of the art and future perspectives","volume":"69","author":"Klareskog","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225727","article-title":"B-cell depletion in autoimmune diseases","volume":"83","author":"Schett","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214833","article-title":"Rituximab in moderate to severe non-renal systemic lupus erythematosus: a reanalysis of the EXPLORER study","volume":"78","author":"Scherlinger","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(1021)00107-00107","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s13317-13017-10100-y","article-title":"Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment","volume":"8","author":"Du","year":"2017","journal-title":"Auto Immun Highlights"},{"key":"B9","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40259-40024-00692-z","article-title":"CAR T-cell therapy for rheumatic diseases: what does the future hold","volume":"39","author":"Avouac","year":"2025","journal-title":"BioDrugs"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152479","article-title":"Advancing autoimmune Rheumatic disease treatment: CAR-T Cell Therapies - Evidence, Safety, and future directions","volume":"67","author":"Ohno","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"B11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nrd.2017.1196","article-title":"FDA approves first CAR T therapy","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - A case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.1009.1002","article-title":"KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2004.00443.x","article-title":"The classification of glomerulonephritis in systemic lupus erythematosus revisited","volume":"65","author":"Weening","year":"2004","journal-title":"Kidney Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200608000-200600015","article-title":"Interobserver reproducibility and application of the ISN\/RPS classification of lupus nephritis-a UK-wide study","volume":"30","author":"Furness","year":"2006","journal-title":"Am J Surg Pathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.1011.1023","article-title":"Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices","volume":"93","author":"Bajema","year":"2018","journal-title":"Kidney Int"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519671","article-title":"CAR-T cell therapy: developments, challenges and expanded applications from cancer to autoimmunity","volume":"15","author":"Kong","year":"2024","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/0961203318817132","article-title":"Disease course patterns in systemic lupus erythematosus","volume":"28","author":"Tselios","year":"2019","journal-title":"Lupus"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(1024)00240-00246","article-title":"Barriers to CAR T-cell therapy in rheumatology","volume":"7","author":"Lungova","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0977","article-title":"Total costs of chimeric antigen receptor T-cell immunotherapy","volume":"4","author":"Hernandez","year":"2018","journal-title":"JAMA Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2217\/rme.2214.2247","article-title":"Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products","volume":"9","author":"Hourd","year":"2014","journal-title":"Regener Med"},{"key":"B25","unstructured":"FDA requires boxed warning for T cell Malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies\n          \n          2024"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1016\/j.jaci.2016.1801.1024","article-title":"Cytometry by time-of-flight immunophenotyping identifies a blood Sj\u00f6gren\u2019s signature correlating with disease activity and glandular inflammation","volume":"137","author":"Mingueneau","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1007\/s00296-00024-05772-00295","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheumatol Int"},{"key":"B29","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.4806.4027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-41022-02017-41595","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24065688","article-title":"CAR T-cell persistence correlates with improved outcome in patients with B-cell lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-3701-552174","article-title":"Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-41018-40010-41591","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-41020-41061-41597","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19751","article-title":"Chimeric antigen receptor T-cell therapy for haematological Malignancies: Insights from fundamental and translational research to bedside practice","volume":"205","author":"Gr\u00e9goire","year":"2024","journal-title":"Br J Haematol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-41021-04390-41586","article-title":"Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells","volume":"602","author":"Melenhorst","year":"2022","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008097","article-title":"Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma","volume":"7","author":"Potnis","year":"2023","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7326\/M1622-2276","article-title":"Second-line chimeric antigen receptor T-cell therapy in diffuse large B-cell lymphoma: A cost-effectiveness analysis","volume":"176","author":"Kelkar","year":"2023","journal-title":"Ann Intern Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.1004.1003","article-title":"Overcoming barriers to referral for chimeric antigen receptor T cell therapy in patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"29","author":"Hoffmann","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2024.2710.2011","article-title":"CAR T cells in autoimmune disease: On the road to remission","volume":"57","author":"Schett","year":"2024","journal-title":"Immunity"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(1024)00377-00371","article-title":"CAR T-cell therapy in autoimmune diseases: where are we and where are we going? Lancet Rheumatol","volume":"7","author":"Scherlinger","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-41025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e179433","DOI":"10.171172\/jci.insight.179433","article-title":"Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2024.102137","article-title":"Outcomes with chimeric antigen receptor T-cell therapy in Rheumatological disorders: A systematic review","volume":"87","author":"Zulfiqar","year":"2024","journal-title":"Transpl Immunol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood-2023-187295","article-title":"CAR T-related toxicities based on dynamic proteomic profiles identifies risk factors for cytokine release syndrome (CRS) and immune effector cell -associated neurotoxicity syndrome (ICANS)","volume":"142","author":"Kewan","year":"2023","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2024.100264","article-title":"Cellular therapies in rheumatic and musculoskeletal diseases","volume":"10","author":"Franco-Fuquen","year":"2025","journal-title":"J Transl Autoimmun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"16011","DOI":"10.1038\/mto.2016.1011","article-title":"Toxicity and management in CAR T-cell therapy","volume":"3","author":"Bonifant","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.1012.1758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(1023)00159-00156","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-41019-40232-41576","article-title":"T(reg) cell-based therapies: challenges and perspectives","volume":"20","author":"Raffin","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.1005.1017","article-title":"Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes","volume":"103","author":"Tenspolde","year":"2019","journal-title":"J Autoimmun"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.720877","article-title":"Novel effects of combination therapy through inhibition of caspase-1\/gasdermin D induced-pyroptosis in lupus nephritis","volume":"12","author":"Cao","year":"2021","journal-title":"Front Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/art.42933","article-title":"Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis","volume":"76","author":"Nicolai","year":"2024","journal-title":"Arthritis Rheumatol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1630569\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:32:26Z","timestamp":1761111146000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1630569\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,22]]},"references-count":57,"alternative-id":["10.3389\/fimmu.2025.1630569"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1630569","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,22]]},"article-number":"1630569"}}